Jim Simons Verona Pharma PLC Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$11.48 - $17.02 $356,385 - $528,368	31,044 New	31,044 $448,000
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $753,066 - $2.47 Million	181,900 Added 645.04%	210,100 $2.15 Million
Q2 2022 Aug 12, 2022	BUY	$3.55 - $5.06 $100,110 - $142,692	28,200 New	28,200 $118,000
Q1 2021 May 13, 2021	SELL	$7.08 - $9.33 $175,584 - $231,384	-24,800 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$5.51 - $8.11 $136,648 - $201,128	24,800 New	24,800 $174,000
Q3 2020 Nov 13, 2020	SELL	$4.45 - $10.2 $95,274 - $218,381	-21,410 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$3.6 - $6.12 $77,076 - $131,029	21,410 New	21,410 $100,000
Q1 2020 May 14, 2020	SELL	$2.16 - $7.28 $27,000 - $91,000	-12,500 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$3.7 - $6.58 $46,250 - $82,250	12,500 New	12,500 $72,000
Q3 2019 Nov 13, 2019	SELL	$4.03 - $5.44 $41,509 - $56,032	-10,300 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$5.1 - $6.91 $7,139 - $9,674	-1,400 Reduced 11.97%	10,300 $53,000
Q1 2019 May 14, 2019	BUY	$5.52 - $10.0 $64,583 - $117,000	11,700 New	11,700 $76,000

167

68.7M

704K

685K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.